Literature DB >> 1384260

CSF neurotransmitter metabolites and short-term outcome of patients in coma after head injury.

M Markianos1, A Seretis, S Kotsou, I Baltas, H Sacharogiannis.   

Abstract

The main metabolites of the neurotransmitters noradrenaline, dopamine, and serotonin, methoxy-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5HIAA) respectively, were estimated by HPLC with electrochemical detection in CSF samples from 24 patients in coma after head injury, 1 to 12 (mean 3.0) days from accident, and from 24 age- and sex-matched subjects undergoing myelography for possible herniated disk. Analysis of variance with age as covariate, revealed significantly elevated levels of all three metabolites in the patients group. The concentrations of 5HIAA were negatively correlated to the score in the Glasgow Coma Scale. Fourteen patients who recovered with no or minor neurological deficits, had significantly lower CSF 5HIAA levels compared to the ten patients who had a bad outcome (death), while there were no differences regarding HVA or MHPG concentrations. The possibility of a connection of the high neurotransmitter turnover during coma to the development of post-traumatic depression is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384260     DOI: 10.1111/j.1600-0404.1992.tb05064.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  CSF neurotransmitter metabolites in comatose head injury patients during changes in their clinical state.

Authors:  M Markianos; A Seretis; A Kotsou; M Christopoulos
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 2.  Neurobiological consequences of traumatic brain injury.

Authors:  Thomas W McAllister
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 3.  Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology.

Authors:  Jenny E Ozga; Jessica M Povroznik; Elizabeth B Engler-Chiurazzi; Cole Vonder Haar
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.